Telo Genomics Corp (TELO) NPV
Telo Genomics Corp, formerly 3D Signatures Inc, is a Canada-based personalized medicine company with a software platform based on the three-dimensional (3D) analysis of telomere organization. Its TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and manage an individual’s disease based on their TeloViewTM score. Its software-based technology and prognostic methodology target various diseases that demonstrate genomic instability, including cancer and neurological disorders. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including TELO-HL, Telo-MM, Telo-PC, Telo-LC and Telo-AD. Its Telo-PC enables clinicians to identify patient stability during diagnosis, optimize treatment plans and manage to monitor with a non-invasive blood test. Its technology analyzes a specific part of an individual’s deoxyribonucleic acid to determine how a disease progress.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.